TY - JOUR
T1 - Cerebrospinal Fluid Biomarkers in Cerebral Amyloid Angiopathy
T2 - New Data and Quantitative Meta-Analysis
AU - Margraf, Nils G
AU - Jensen-Kondering, Ulf
AU - Weiler, Caroline
AU - Leypoldt, Frank
AU - Maetzler, Walter
AU - Philippen, Sarah
AU - Bartsch, Thorsten
AU - Flüh, Charlotte
AU - Röcken, Christoph
AU - Möller, Bettina
AU - Royl, Georg
AU - Neumann, Alexander
AU - Brüggemann, Norbert
AU - Roeben, Benjamin
AU - Schulte, Claudia
AU - Bender, Benjamin
AU - Berg, Daniela
AU - Kuhlenbäumer, Gregor
N1 - Publisher Copyright:
Copyright © 2022 Margraf, Jensen-Kondering, Weiler, Leypoldt, Maetzler, Philippen, Bartsch, Flüh, Röcken, Möller, Royl, Neumann, Brüggemann, Roeben, Schulte, Bender, Berg and Kuhlenbäumer.
PY - 2022/2/14
Y1 - 2022/2/14
N2 - Background: To evaluate the diagnostic accuracy of cerebrospinal fluid (CSF) biomarkers in patients with probable cerebral amyloid angiopathy (CAA) according to the modified Boston criteria in a retrospective multicentric cohort.Methods: Beta-amyloid 1-40 (Aβ40), beta-amyloid 1-42 (Aβ42), total tau (t-tau), and phosphorylated tau 181 (p-tau181) were measured in 31 patients with probable CAA, 28 patients with Alzheimer's disease (AD), and 30 controls. Receiver-operating characteristics (ROC) analyses were performed for the measured parameters as well as the Aβ42/40 ratio to estimate diagnostic parameters. A meta-analysis of all amenable published studies was conducted.Results: In our data Aβ42/40 (AUC 0.88) discriminated best between CAA and controls while Aβ40 did not perform well (AUC 0.63). Differentiating between CAA and AD, p-tau181 (AUC 0.75) discriminated best in this study while Aβ40 (AUC 0.58) and Aβ42 (AUC 0.54) provided no discrimination. In the meta-analysis, Aβ42/40 (AUC 0.90) showed the best discrimination between CAA and controls followed by t-tau (AUC 0.79), Aβ40 (AUC 0.76), and p-tau181 (AUC 0.71). P-tau181 (AUC 0.76), Aβ40 (AUC 0.73), and t-tau (AUC 0.71) differentiated comparably between AD and CAA while Aβ42 (AUC 0.54) did not. In agreement with studies examining AD biomarkers, Aβ42/40 discriminated excellently between AD and controls (AUC 0.92-0.96) in this study as well as the meta-analysis.Conclusion: The analyzed parameters differentiate between controls and CAA with clinically useful accuracy (AUC > ∼0.85) but not between CAA and AD. Since there is a neuropathological, clinical and diagnostic continuum between CAA and AD, other diagnostic markers, e.g., novel CSF biomarkers or other parameters might be more successful.
AB - Background: To evaluate the diagnostic accuracy of cerebrospinal fluid (CSF) biomarkers in patients with probable cerebral amyloid angiopathy (CAA) according to the modified Boston criteria in a retrospective multicentric cohort.Methods: Beta-amyloid 1-40 (Aβ40), beta-amyloid 1-42 (Aβ42), total tau (t-tau), and phosphorylated tau 181 (p-tau181) were measured in 31 patients with probable CAA, 28 patients with Alzheimer's disease (AD), and 30 controls. Receiver-operating characteristics (ROC) analyses were performed for the measured parameters as well as the Aβ42/40 ratio to estimate diagnostic parameters. A meta-analysis of all amenable published studies was conducted.Results: In our data Aβ42/40 (AUC 0.88) discriminated best between CAA and controls while Aβ40 did not perform well (AUC 0.63). Differentiating between CAA and AD, p-tau181 (AUC 0.75) discriminated best in this study while Aβ40 (AUC 0.58) and Aβ42 (AUC 0.54) provided no discrimination. In the meta-analysis, Aβ42/40 (AUC 0.90) showed the best discrimination between CAA and controls followed by t-tau (AUC 0.79), Aβ40 (AUC 0.76), and p-tau181 (AUC 0.71). P-tau181 (AUC 0.76), Aβ40 (AUC 0.73), and t-tau (AUC 0.71) differentiated comparably between AD and CAA while Aβ42 (AUC 0.54) did not. In agreement with studies examining AD biomarkers, Aβ42/40 discriminated excellently between AD and controls (AUC 0.92-0.96) in this study as well as the meta-analysis.Conclusion: The analyzed parameters differentiate between controls and CAA with clinically useful accuracy (AUC > ∼0.85) but not between CAA and AD. Since there is a neuropathological, clinical and diagnostic continuum between CAA and AD, other diagnostic markers, e.g., novel CSF biomarkers or other parameters might be more successful.
UR - http://www.scopus.com/inward/record.url?scp=85125866816&partnerID=8YFLogxK
UR - https://www.mendeley.com/catalogue/0be6054a-f4dc-37d3-a791-8f913ea1379f/
U2 - 10.3389/fnagi.2022.783996
DO - 10.3389/fnagi.2022.783996
M3 - Journal articles
C2 - 35237145
SN - 1663-4365
VL - 14
SP - 783996
JO - Frontiers in Aging Neuroscience
JF - Frontiers in Aging Neuroscience
M1 - 783996
ER -
